|
| |
ostarine september Pages on BioPortfolio:
BioPortfolio - GTX
GTx believes that ostarine has the potential to treat a variety of indications, ... 20th September, 2008, Preclinical Research and Development, GTx, Inc., ...
http://www.bioportfolio.com/biocorporate/32439-GTX.html...
|
Biotechnology News Multiple Endocrine Neoplasia Endocrine Search
GTx Announces Investigational Ostarine MK-2866 Met the Primary Endpoint in the ... 5 September/October 2008 A 16-year-old girl was admitted with severe ...
http://www.bioportfolio.co.uk/Multiple%20Endocrine%20Neoplas...
|
BioPortfolio - GTX - Profile
GTx plans to initiate a Phase IIb ostarine clinical trial for cancer ... receptor (AR) ligands are important for the development and...20th September,
2008 ...
http://www.bioportfolio.com/biocorporate/32439-GTX.pdf...
|
Biotechnology News Neoplastic Endocrine-Like s Search
GTx Announces Investigational Ostarine MK-2866 Met the Primary Endpoint in the ... Institute Advance Access originally published online on September 23, ...
http://www.bioportfolio.co.uk/Neoplastic%2520Endocrine-Like%...
|
BioPortfolio - Gait Apraxia - InDepth
... hydrocephalus (NPH), the physiological alterations...2nd September, 2006 ... GTx Announces Investigational Ostarine MK-2866 Met the Primary Endpoint in ...
http://www.bioportfolio.com/indepth/Gait_Apraxia.pdf...
|
Biotechnology News oncology cancer angulo. burstein. wolff ...
... More: Highlights of the 19th Annual Clinical Meeting CME/CE September 8 . ... II study of 159 cancer patients showed that the drug candidate Ostarine. ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=e...
|
Biotechnology News Guillain-Barre terpolym. 0250. copolym. mhc ...
was funded in September 2002 in response to NIMH RFA 00-AI-0005 to ... GTx Announces Investigational Ostarine MK-2866 Met the Primary Endpoint in the Phase
...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=e...
|
Biotechnology News Endocrine Neoplasm Search
GTx Announces Investigational Ostarine MK-2866 Met the Primary Endpoint in the Phase ... today announced results for the quarter ended September 30, 2008. ...
http://www.bioportfolio.co.uk/Endocrine%2520Neoplasm-news.ht...
|
Biotechnology News Search
The drug candidate, called Ostarine, is being developed with. ..... A year ago in the quarter ended September, Affymetrix (NASDAQ: AFFX) had sales of $95 ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?DB=ne...
|
Results from other life science and pharmaceutical sites:
BioPortfolio - GTX
GTx believes that ostarine has the potential to treat a variety of indications, ... 20th September, 2008, Preclinical Research and Development, GTx, Inc., ...
http://www.bioportfolio.com/biocorporate/32439-GTX.html...
|
News: GTx, Inc. Reports Third Quarter 2008 Financial Results ...
At September 30, 2008 GTx had cash, cash equivalents and short-term ... GTx and Merck & Co., Inc. are collaborating to develop Ostarine(TM) and other SARMs, ...
http://www.genengnews.com/news/bnitem.aspx?name=44923756...
|
BioPortfolio - GTX - Profile
GTx plans to initiate a Phase IIb ostarine clinical trial for cancer ... receptor (AR) ligands are important for the development and...20th September,
2008 ...
http://www.bioportfolio.com/biocorporate/32439-GTX.pdf...
|
LICENSING PRESS RELEASES LICENSING PRESS RELEASES
ROCKVILLE, MD, September 17, 2007 .... lead SARM candidate, OSTARINE ... ization of OSTARINE and other investigational SARMs resulting from the ...
http://www.merck.com/licensing/pdf/press_releases.pdf...
|
GTx Presents Bone Turnover Marker Data and Additional PSA ...
Tuesday September 16, 12:30 pm ET. MONTREAL--(BUSINESS WIRE)--GTx, .... Ostarine is also in a Phase II clinical trial for cancer cachexia which will be ...
http://biz.yahoo.com/bw/080916/20080916006097.html?.v=1...
|
Deal Highlights
began recruiting patients in September 2007. ... A US $220 million alliance from September 2002 between .... Merck acquires GTx's ostarine ...
http://www.biomedcentral.com/content/pdf/cd-854598.pdf...
|
BioPortfolio - Gait Apraxia - InDepth
... hydrocephalus (NPH), the physiological alterations...2nd September, 2006 ... GTx Announces Investigational Ostarine MK-2866 Met the Primary Endpoint in ...
http://www.bioportfolio.com/indepth/Gait_Apraxia.pdf...
|
Patent alert
the treatment of benign prostatic hypertrophy, ostarine for. male osteoporosis and andropause, and andromustine for ... WO-2004074244, 02 September 2004 ...
http://www.biomedcentral.com/content/pdf/cd-568470.pdf...
|
|
